JP2019528242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528242A5 JP2019528242A5 JP2018565888A JP2018565888A JP2019528242A5 JP 2019528242 A5 JP2019528242 A5 JP 2019528242A5 JP 2018565888 A JP2018565888 A JP 2018565888A JP 2018565888 A JP2018565888 A JP 2018565888A JP 2019528242 A5 JP2019528242 A5 JP 2019528242A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- seq
- amino acid
- polypeptide
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 63
- 229920001184 polypeptide Polymers 0.000 claims description 60
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 60
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 150000001413 amino acids Chemical group 0.000 claims description 44
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 239000012521 purified sample Substances 0.000 claims description 20
- 239000000523 sample Substances 0.000 claims description 16
- 230000004989 O-glycosylation Effects 0.000 claims description 12
- 239000012149 elution buffer Substances 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 230000010100 anticoagulation Effects 0.000 claims description 6
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- OZBJWQQAAQSQPL-WCCKRBBISA-N acetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N OZBJWQQAAQSQPL-WCCKRBBISA-N 0.000 claims description 3
- 238000005349 anion exchange Methods 0.000 claims description 3
- 230000003042 antagnostic effect Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- AJDONJVWDSZZQF-UHFFFAOYSA-N 1-(2,4,4-trimethylpentan-2-yl)-4-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]benzene Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OC1=CC=C(C(C)(C)CC(C)(C)C)C=C1 AJDONJVWDSZZQF-UHFFFAOYSA-N 0.000 claims description 2
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000013504 Triton X-100 Substances 0.000 claims description 2
- 229920004890 Triton X-100 Polymers 0.000 claims description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000009697 arginine Nutrition 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- 239000000919 ceramic Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 2
- 239000003014 ion exchange membrane Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000002753 trypsin inhibitor Substances 0.000 claims description 2
- 238000011097 chromatography purification Methods 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021165271A JP7273918B2 (ja) | 2016-06-17 | 2021-10-07 | 第ｘａ因子誘導体の調製 |
| JP2023074627A JP2023086970A (ja) | 2016-06-17 | 2023-04-28 | 第ｘａ因子誘導体の調製 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351841P | 2016-06-17 | 2016-06-17 | |
| US62/351,841 | 2016-06-17 | ||
| PCT/US2017/038169 WO2017219034A2 (en) | 2016-06-17 | 2017-06-19 | Preparation of factor xa derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021165271A Division JP7273918B2 (ja) | 2016-06-17 | 2021-10-07 | 第ｘａ因子誘導体の調製 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528242A JP2019528242A (ja) | 2019-10-10 |
| JP2019528242A5 true JP2019528242A5 (enExample) | 2020-06-11 |
| JP6959268B2 JP6959268B2 (ja) | 2021-11-02 |
Family
ID=60663351
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565888A Active JP6959268B2 (ja) | 2016-06-17 | 2017-06-19 | 第ｘａ因子誘導体の調製 |
| JP2021165271A Active JP7273918B2 (ja) | 2016-06-17 | 2021-10-07 | 第ｘａ因子誘導体の調製 |
| JP2023074627A Pending JP2023086970A (ja) | 2016-06-17 | 2023-04-28 | 第ｘａ因子誘導体の調製 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021165271A Active JP7273918B2 (ja) | 2016-06-17 | 2021-10-07 | 第ｘａ因子誘導体の調製 |
| JP2023074627A Pending JP2023086970A (ja) | 2016-06-17 | 2023-04-28 | 第ｘａ因子誘導体の調製 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US10604748B2 (enExample) |
| EP (3) | EP3472314B1 (enExample) |
| JP (3) | JP6959268B2 (enExample) |
| KR (1) | KR102373215B1 (enExample) |
| CN (3) | CN116425860B (enExample) |
| AU (2) | AU2017283720C1 (enExample) |
| CA (1) | CA3027457A1 (enExample) |
| CL (2) | CL2018003654A1 (enExample) |
| CO (1) | CO2019000120A2 (enExample) |
| DK (1) | DK3472314T3 (enExample) |
| EA (1) | EA037815B1 (enExample) |
| ES (2) | ES3038834T3 (enExample) |
| HU (1) | HUE054597T2 (enExample) |
| IL (1) | IL263591B2 (enExample) |
| MX (1) | MX2018015873A (enExample) |
| PE (1) | PE20190661A1 (enExample) |
| PH (1) | PH12018502614A1 (enExample) |
| PL (1) | PL3472314T3 (enExample) |
| PT (1) | PT3472314T (enExample) |
| SG (1) | SG11201810915QA (enExample) |
| SI (1) | SI3472314T1 (enExample) |
| WO (1) | WO2017219034A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3604510B1 (en) * | 2009-03-30 | 2025-03-26 | Alexion Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
| SG10201705189XA (en) * | 2013-01-24 | 2017-07-28 | Portola Pharm Inc | INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES |
| EP3472314B1 (en) * | 2016-06-17 | 2021-05-05 | Alexion Pharmaceuticals, Inc. | Preparation of factor xa derivatives |
| US12195774B2 (en) | 2018-06-19 | 2025-01-14 | Alexion Pharmaceuticals, Inc. | Antidotes to factor XA inhibitors |
| KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189019A (en) * | 1990-04-23 | 1993-02-23 | Merck & Co., Inc. | Antistasin derived anticoagulant protein |
| US5589571A (en) * | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
| JPH1066572A (ja) * | 1996-08-29 | 1998-03-10 | Showa Sangyo Co Ltd | 高純度の大豆トリプシンインヒビターの製造方法 |
| CA2401778C (en) | 2000-02-29 | 2010-12-21 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| PT1948608E (pt) | 2005-11-08 | 2012-05-24 | Millennium Pharm Inc | Novos sais farmacêuticos e polimorfos de um inibidor do fator xa |
| PT3078743T (pt) * | 2007-09-28 | 2020-07-15 | Portola Pharm Inc | Antídotos para inibidores do fator xa e métodos de utilização dos mesmos |
| US8455439B2 (en) | 2008-11-14 | 2013-06-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents |
| EP3604510B1 (en) * | 2009-03-30 | 2025-03-26 | Alexion Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
| WO2011008885A1 (en) * | 2009-07-15 | 2011-01-20 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
| CA2876361C (en) * | 2012-06-14 | 2020-06-30 | Portola Pharmaceuticals, Inc. | Method for purification of recombinant factor xa derivatives |
| US20140346397A1 (en) * | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| SG10201705189XA (en) | 2013-01-24 | 2017-07-28 | Portola Pharm Inc | INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES |
| KR101988705B1 (ko) * | 2013-09-24 | 2019-06-12 | 화이자 인코포레이티드 | 재조합 인간 응고 인자 Xa 단백질의 이질적 집단을 포함하는 조성물 |
| AU2015305413B2 (en) * | 2014-08-20 | 2020-09-24 | Alexion Pharmaceuticals, Inc. | Lyophilized formulations for factor xa antidote |
| EP3472314B1 (en) * | 2016-06-17 | 2021-05-05 | Alexion Pharmaceuticals, Inc. | Preparation of factor xa derivatives |
-
2017
- 2017-06-19 EP EP17814267.5A patent/EP3472314B1/en active Active
- 2017-06-19 JP JP2018565888A patent/JP6959268B2/ja active Active
- 2017-06-19 MX MX2018015873A patent/MX2018015873A/es unknown
- 2017-06-19 EP EP21164923.1A patent/EP3926044B1/en active Active
- 2017-06-19 US US15/626,813 patent/US10604748B2/en active Active
- 2017-06-19 DK DK17814267.5T patent/DK3472314T3/da active
- 2017-06-19 SG SG11201810915QA patent/SG11201810915QA/en unknown
- 2017-06-19 KR KR1020197000840A patent/KR102373215B1/ko active Active
- 2017-06-19 EA EA201990052A patent/EA037815B1/ru not_active IP Right Cessation
- 2017-06-19 IL IL263591A patent/IL263591B2/en unknown
- 2017-06-19 PE PE2018003241A patent/PE20190661A1/es unknown
- 2017-06-19 ES ES21164923T patent/ES3038834T3/es active Active
- 2017-06-19 HU HUE17814267A patent/HUE054597T2/hu unknown
- 2017-06-19 CN CN202310427500.2A patent/CN116425860B/zh active Active
- 2017-06-19 CA CA3027457A patent/CA3027457A1/en active Pending
- 2017-06-19 CN CN201780041530.2A patent/CN110167575B/zh active Active
- 2017-06-19 CN CN202410192888.7A patent/CN118271391A/zh active Pending
- 2017-06-19 EP EP25172582.6A patent/EP4588932A3/en active Pending
- 2017-06-19 ES ES17814267T patent/ES2875538T3/es active Active
- 2017-06-19 AU AU2017283720A patent/AU2017283720C1/en active Active
- 2017-06-19 PT PT178142675T patent/PT3472314T/pt unknown
- 2017-06-19 SI SI201730865T patent/SI3472314T1/sl unknown
- 2017-06-19 PL PL17814267T patent/PL3472314T3/pl unknown
- 2017-06-19 WO PCT/US2017/038169 patent/WO2017219034A2/en not_active Ceased
-
2018
- 2018-12-11 PH PH12018502614A patent/PH12018502614A1/en unknown
- 2018-12-17 CL CL2018003654A patent/CL2018003654A1/es unknown
-
2019
- 2019-01-09 CO CONC2019/0000120A patent/CO2019000120A2/es unknown
-
2020
- 2020-01-10 US US16/740,001 patent/US10954504B2/en active Active
- 2020-06-25 CL CL2020001733A patent/CL2020001733A1/es unknown
-
2021
- 2021-03-09 US US17/196,172 patent/US11845966B2/en active Active
- 2021-10-07 JP JP2021165271A patent/JP7273918B2/ja active Active
-
2023
- 2023-02-14 AU AU2023200825A patent/AU2023200825A1/en active Pending
- 2023-04-28 JP JP2023074627A patent/JP2023086970A/ja active Pending
- 2023-11-08 US US18/505,022 patent/US20240076642A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528242A5 (enExample) | ||
| JP6593721B2 (ja) | 高純度の組換えヒト血清アルブミンを単離、精製するクロマトグラフ法 | |
| JP2022028833A (ja) | 抗菌療法 | |
| EP1268551B1 (en) | A METHOD OF PRODUCING IgG | |
| KR101925695B1 (ko) | 고순도 반코마이신 염산염의 분리 정제방법 | |
| CN106474470B (zh) | 一种抗il-17a抗体的组合物 | |
| JP2016504040A5 (enExample) | ||
| CN105017412B (zh) | 一种从牛血清中分离高纯度牛血清白蛋白的方法 | |
| CN103159829B (zh) | 达托霉素的提取方法 | |
| RU2014123990A (ru) | Антитело к адреномедуллину (adm) или фрагмент анти-adm антитела, или анти-adm he-iq каркас для применения в терапии | |
| JP2018515766A (ja) | ポリペプチド混合物の高速液体クロマトグラフィー分析方法 | |
| RU2358980C2 (ru) | Способ очистки и/или выделения биологически активного гранулоцитарного колониестимулирующего фактора | |
| CN102718839A (zh) | 一种分离纯化达托霉素的方法 | |
| WO1990003395A1 (fr) | Nouveaux polypeptides physiologiquement actifs, plasmide recombinant, cellules microbiennes recombinantes, preparation medicinale et procede d'extraction de polypeptide purifie | |
| JP2018507175A5 (enExample) | ||
| CN102441172A (zh) | 高纯度凝血酶原复合物制品冷冻干燥稳定剂 | |
| WO2023024214A1 (zh) | 纯化重组人血清白蛋白的融合蛋白的方法 | |
| CN101525382B (zh) | 一种纯化普兰林肽的方法 | |
| CN105435221B (zh) | 一种针对血管内皮生长因子的人源化抗体的药物组合物 | |
| JP6303379B2 (ja) | 抗体の精製方法 | |
| CN104936610A (zh) | Glp-1类似物的纯化方法 | |
| CN115850383A (zh) | 一种雷扎芬净纯化方法 | |
| CN106565827B (zh) | 一种高度纯化糖肽类化合物的方法 | |
| CN106866789A (zh) | 一种分离纯化达托霉素rs-8杂质的方法 | |
| WO2017154869A1 (ja) | 変異型ヒトエリスロポエチンの製造方法 |